Novartis reports Q3 core EPS $2.46 vs. $2.25 last year

Novartis reported Q3 2026 core EPS of $2.46, up from $2.25 last year, with net sales reaching $14.5B, an increase from $13.9B. CEO Vas Narasimhan attributed growth to strong brand performance and productivity. The company upgraded its full-year guidance and highlighted pipeline advancements, including positive Phase III results for remibrutinib and EU submission for pelabresib. Despite a setback in del-desiran, progress continues in FSHD and DMD programs.

Original reporting
Published Oct 27, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 10:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$NVSBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term price appreciation, while mixed trial results may introduce volatility.

02

Market read

First‑report earnings beat and guidance upgrade for a large‑cap pharma company, with potential sector‑wide ripple effects.

03

What to watch

Potential headwinds from the less‑than‑expected readout in DM1 and ongoing regulatory scrutiny could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Novartis highlighted solid sales growth, pipeline progress with Phase III data, and a mixed readout in DM1.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis reported Q3 net sales of $14.5B and core EPS of $2.46, beating prior year and upgrading full-year guidance.

Expected impact

likely upward pressure as investors price in higher guidance

Evidence & confidence

The surprise EPS beat and guidance raise are fresh, material information for a large‑cap pharma stock.

Market effects

Boosts sentiment for the broader pharma/healthcare sector as earnings beat may lift peers.

Positive for European markets where Novartis is a major component.

Adds to global growth narrative for large‑cap biotech and pharma companies.

Counterpoint

If the guidance upgrade is modest, the market may have already priced it in, limiting upside.

Key entities

  • Vas Narasimhan

    CEO of Novartis, provided commentary on earnings and pipeline.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.